• Corpus ID: 19765630

Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low-molecular-weight heparin treatment?

@article{Kalk2004RecurrenceRO,
  title={Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low-molecular-weight heparin treatment?},
  author={Jakoba J Kalk and Anjoke J. M. Huisjes and Christianne J.M. de Groot and Erik van Beek and Mari{\"e}lle G. van Pampus and Marc Ea Spaanderman and Jim van Eyck and S. Guid Oei and P. Dick Bezemer and Jip de Vries},
  journal={The Netherlands journal of medicine},
  year={2004},
  volume={62 3},
  pages={
          83-7
        },
  url={https://api.semanticscholar.org/CorpusID:19765630}
}
The recurrence rate of pre-eclampsia in women with thrombophilic disorders is high in this small retrospective study and no positive effect was found for LMWH treatment.
View on PubMed
web.archive.org
35 Citations
Highly Influential Citations
3
Background Citations
6
Results Citations
1

Tables from this paper

35 Citations

Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.

Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies

A practical evidence based list of clinical risk factors that can be assessed by a clinician at ≤16 weeks’ gestation to estimate a woman’s risk of pre-eclampsia and the use of aspirin prophylaxis in pregnancy is developed.

Does low-dose aspirin initiated before 11 weeks ’ gestation reduce the rate of 1 preeclampsia ? 2

A systematic review and meta-analysis evaluated the effect of low-dose aspirin initiated at <11 weeks’ gestation on the risk of preeclampsia, gestational hypertension, or any hypertensive disorder of pregnancy in women with a history of recurrent pregnancy loss.

Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia?

The administration of low-dose aspirin at <11 weeks' gestation in high risk women does not decrease the risk of preeclampsia, gestational hypertension, any hypertensive disorder of pregnancy and fetal growth restriction, but it might reduce therisk of preterm delivery.

Antiphospholipid Syndrome and Pre-Eclampsia

According to the retrospective observation, the determination of anticardiolipin antibodies, lupus anticoagulant, and b -2 glycoprotein-1 antibodies in patients with severe P-EC at < 34 weeks of gestation are recommended.

Low‐molecular‐weight heparin added to aspirin in the prevention of recurrent early‐onset pre‐eclampsia in women with inheritable thrombophilia: the FRUIT‐RCT

Adding low‐molecular‐weight heparin to aspirin at <’12 weeks gestation reduces the recurrence of HD in women with previous early‐onset HD and/or SGA and in the context of inheritable thrombophilia without antiphospholipid antibodies.

Thrombophilia and Pre-Eclampsia

This review addresses the association between P-EC and thrombophilia, its concerns, and the necessity of screening after a pregnancy complicated by hypertension.

Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation

The evidence suggests a benefit of LMWH in the reduction of recurrences of APOs, with a number needed to treat of 6 (95% confidence interval: 4–10) to prevent one case of recurrent APOs.

[Hereditary thrombophilias and placental-mediated pregnancy complications in the II./III. trimester].

Large, well-designed multicenter studies are needed to elucidate the role of hereditary thrombophilias in cases of PmC and to confirm the benefit of LWH for subsequent pregnancy outcomes.

Genetic risk assessment of thrombophilia in patients with adverse obstetric outcomes

Although some association may exist between hypercoagulability and pregnancy outcomes, no significant direct correlation was observed between adverse obstetric outcomes and inherited thrombophilias when analyzed using either standard blood tests or the genetic test.

24 References

Low-Molecular-Weight Heparin for the Prevention of Obstetric Complications in Women with Thrombophilias

This uncontrolled trial suggests that patients with obstetric complications and an inherited thrombophilia may benefit from treatment with combined LMW heparin and aspirin in subsequent pregnancies, but this needs to be verified by controlled trials before considering clinical application.

Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study.

Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review

It is concluded that low-molecular-weight heparins (LMWH) appear to be a safe alternative to unfractionated heparin as an anticoagulant during pregnancy.

The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations.

Use of Low Molecular Weight Heparin in Pregnancy

It is concluded that LMW heparin does not cross the placental barrier, and in addition offers satisfactory antithrombotic protection for both maternal and placental circulation.

Increased frequency of genetic thrombophilia in women with complications of pregnancy.

Women with serious obstetrical complications have an increased incidence of mutations predisposing them to thrombosis and other inherited and acquired forms ofThrombophilia.

Long-term follow-up in patients with a history of (H)ELLP syndrome.

(H)ELLP syndrome is a severe complication of pregnancy that has not only short-term but also long-term sequelae andMultiparity, gestational age at delivery <30 weeks, and birth weight in the index pregnancy increased the risk of recurrence of GH in the first subsequent pregnancy significantly.

Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis.

High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

The prognosis for pregnancies in women with recurrent miscarriage associated with phospholipid antibodies is poor but this randomised controlled trial found that the prognosis improved with low dose aspirin and was further improved with the addition of low dose heparin to the aspirin.